Breast and Ovarian Cancer Risk and Prevention
Research Studies
Statins and Breast Cancer Biomarkers
Why is this study being done?
Atorvastatin (Lipitor) is a drug approved by the U.S. Food and Drug Administration (FDA) that belongs to a class of drugs called statins. Statins have been useful in lowering cholesterol and rates of coronary heart disease. Statins also appear to reduce heart disease risk through their anti-inflammatory actions. It is thought that the anti-inflammatory activity of statins may be important in reducing cancer risk.
The purpose of this study is to determine if taking Atorvastatin has an effect on breast density, a known risk factor for developing breast cancer.
What is Atorvatsatin?
Atorvastatin, also referred to as Lipitor, is one member of a family of medicines called "statins." Atorvastatin is currently FDA-approved for treatment of high cholesterol and prevention of heart attacks and has been in use for over a decade.
Who can participate in this study?
This study is open to pre-menopausal women 35 years and older who are at increased risk of developing breast cancer.
What is involved in participating?
After you have signed the consent form, tests will be done before you begin taking Atorvastatin.
These tests include:
- Medical history
- Physical examination
- Blood tests
- A mammogram
- Questionnaires about your diet and lifestyle
You will be randomized (a 50/50 chance) to take either Atorvastatin or a placebo (sugar pill) daily for one year.
While you are on the study you will undergo an annual mammogram, as well as quarterly blood draws.
How can I get more information about the trial?
Hannah Green, MPH
hannah_green@dfci.harvard.edu
(617) 632-2359
